Detalle de acción
BRVE
Braveheart Bio, Inc.
-
-
-
-
| Capitalización | - |
|---|---|
| Volumen | - |
| Rango del día | - |
| Ingresos (TTM) | - |
| Ingreso neto | - |
| EPS | - |
| Acciones en circulación | - |
| PE | - |
| PE forward | - |
| Dividendo | - |
| Fecha ex-dividendo | - |
| Open | - |
| Close anterior | - |
| Rango 52 semanas | - |
| Beta | - |
| Analistas | - |
| Precio objetivo | - |
| Fecha de resultados | - |
Cargando...
Acerca de brve
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM.
The company was incorporated in 2024 and is headquartered in San Francisco, California.
Industria
Biotecnología
Sector
Salud
Fecha de IPO
Aug 6, 2026
Empleados
-
Bolsa
NASDAQ
Sitio web
braveheart.bio
PUBLICIDAD